EuroPCR 2023: Late-Breaking Science Video Collection

Published: 18 May 2023

  • Views:

    Views Icon 1935
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.

 

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

 

Hear commentary on the practice-changing trials of EuroPCR 2023 from selected faculty in our Highlights Reviews.

 

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of EuroPCR 2023. 

More from this programme

Part 2

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at EuroPCR 2023. 

Part 3

Highlights Reviews

Commentary on the top late-breaking trials of EuroPCR 2023, as chosen by selected faculty.

Part 4

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

About the episode

EuroPCR 23 — We are joined onsite by Dr Sandeep Arunothayaraj (University Hospitals Sussex NHS Foundation Trust, UK) to discuss the findings from a five-year follow-up of the EBC Two Trial. (NCT01560455)

EBC Two investigated single-stent versus dual-stent techniques in treating large bifurcation lesions. Over 200 patients were enrolled in the trial. The study found that routine culotte did not improve 5-year MACE in non-left main true bifurcations compared to provisional stenting. Side branch disease length did not affect this result. Only 16% of provisional patients required a second stent, resulting in significant savings in cost, radiation, time and potential procedural complications. These findings strongly support using the provisional strategy as the default approach for bifurcation disease.

Interview Questions:

  1. What is the background of this study?
  2. What was the study design, patient population and outcome measures?
  3. What were the key findings presented at EuroPCR?
  4. How were operator experience and expertise accounted for in the trial?
  5. Based on these findings which patients would benefit from a provisional T-stent strategy?
  6. What are the potential implications for clinical practice?
  7. What are the next steps?

Recorded on-site at EuroPCR 2023, Paris.

Editors: Jordan Rance and Mirjam Boros

Video Specialists: Oliver Miles and Dan Brent

Faculty Biographies

Sandeep Arunothayaraj

View full profile

Comments

You must be to comment. If you are not registered, you can register here.